Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamel Laribi

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|August 18, 2018
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF studyEmmanuel Gyan, Anne Sonet, Pauline Brice, et al.
Blood|February 14, 2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinibDavid Ghez, Anne Calleja, Caroline Protin, et al.
Ejhaem|February 26, 2024
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN studyKamel Laribi, Xavier Leleu, Nathalie Texier, et al.
European Journal of Haematology|September 16, 2018
Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control studyNadege Wesner, Louis Drevon, Alexis Guedon, et al.
Blood|April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMAndrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelinesDamien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, et al.
Kidney International Reports|December 18, 2023
Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe DiseaseMarie-Camille Lafargue, Mickaël Bobot, Helmut G Rennke, et al.
Leukemia & Lymphoma|November 21, 2018
Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature reviewNadege Wesner, Louis Drevon, Alexis Guedon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell LymphomaNancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trialMurielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|August 18, 2018
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF studyEmmanuel Gyan, Anne Sonet, Pauline Brice, et al.
Blood|February 14, 2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinibDavid Ghez, Anne Calleja, Caroline Protin, et al.
Ejhaem|February 26, 2024
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN studyKamel Laribi, Xavier Leleu, Nathalie Texier, et al.
European Journal of Haematology|September 16, 2018
Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control studyNadege Wesner, Louis Drevon, Alexis Guedon, et al.
Blood|April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMAndrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelinesDamien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, et al.
Kidney International Reports|December 18, 2023
Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe DiseaseMarie-Camille Lafargue, Mickaël Bobot, Helmut G Rennke, et al.
Leukemia & Lymphoma|November 21, 2018
Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature reviewNadege Wesner, Louis Drevon, Alexis Guedon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell LymphomaNancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trialMurielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
Pageof 11